Apex Labs announced Health Canada approval of the company's secondary US-based supplier of good manufacturing practices (GMP) psilocybin active pharmaceutical ingredient (API) in addition to its existing primary Canadian-based supplier.
APEX is actively shipping the drug across the Canadian-US border with permit approvals from Health Canada, the Drug Enforcement Administration (DEA), and US customs. Health Canada authorization was received for the secondary manufacturer by way of a Clinical Trial Application (CTA) amendment.